Cargando…
Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis
BACKGROUND AND AIM: The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the most common cause of CLD, has been controversial. Here, we investigated the impact of cannabis use on the prevalence of CLD among HCV infected individuals. METHODS: We analyzed h...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174743/ https://www.ncbi.nlm.nih.gov/pubmed/30345261 http://dx.doi.org/10.1155/2018/9430953 |
_version_ | 1783361332701036544 |
---|---|
author | Adejumo, Adeyinka Charles Adegbala, Oluwole Muyiwa Adejumo, Kelechi Lauretta Bukong, Terence Ndonyi |
author_facet | Adejumo, Adeyinka Charles Adegbala, Oluwole Muyiwa Adejumo, Kelechi Lauretta Bukong, Terence Ndonyi |
author_sort | Adejumo, Adeyinka Charles |
collection | PubMed |
description | BACKGROUND AND AIM: The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the most common cause of CLD, has been controversial. Here, we investigated the impact of cannabis use on the prevalence of CLD among HCV infected individuals. METHODS: We analyzed hospital discharge records of adults (age ≥ 18 years) with a positive HCV diagnosis. We evaluated records from 2007 to 2014 of the Nationwide Inpatient Sample (NIS). We excluded records with other causes of chronic liver diseases (alcohol, hemochromatosis, NAFLD, PBC, HBV, etc.). Of the 188,333 records, we matched cannabis users to nonusers on 1:1 ratio (4,728:4,728), using a propensity-based matching system, with a stringent algorithm. We then used conditional regression models with generalized estimating equations to measure the adjusted prevalence rate ratio (aPRR) for having liver cirrhosis (and its complications), carcinoma, mortality, discharge disposition, and the adjusted mean ratio (aMR) of total hospital cost and length of stay (LOS) [SAS 9.4]. RESULTS: Our study revealed that cannabis users (CUs) had decreased prevalence of liver cirrhosis (aPRR: 0.81[0.72-0.91]), unfavorable discharge disposition (0.87[0.78-0.96]), and lower total health care cost ($39,642[36,220-43,387] versus $45,566[$42,244-$49,150]), compared to noncannabis users (NCUs). However, there was no difference among CUs and NCUs on the incidence of liver carcinoma (0.79[0.55-1.13]), in-hospital mortality (0.84[0.60-1.17]), and LOS (5.58[5.10-6.09] versus 5.66[5.25-6.01]). Among CUs, dependent cannabis use was associated with lower prevalence of liver cirrhosis, compared to nondependent use (0.62[0.41-0.93]). CONCLUSIONS: Our findings suggest that cannabis use is associated with decreased incidence of liver cirrhosis, but no change in mortality nor LOS among HCV patients. These novel observations warrant further molecular mechanistic studies. |
format | Online Article Text |
id | pubmed-6174743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-61747432018-10-21 Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis Adejumo, Adeyinka Charles Adegbala, Oluwole Muyiwa Adejumo, Kelechi Lauretta Bukong, Terence Ndonyi Can J Gastroenterol Hepatol Research Article BACKGROUND AND AIM: The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the most common cause of CLD, has been controversial. Here, we investigated the impact of cannabis use on the prevalence of CLD among HCV infected individuals. METHODS: We analyzed hospital discharge records of adults (age ≥ 18 years) with a positive HCV diagnosis. We evaluated records from 2007 to 2014 of the Nationwide Inpatient Sample (NIS). We excluded records with other causes of chronic liver diseases (alcohol, hemochromatosis, NAFLD, PBC, HBV, etc.). Of the 188,333 records, we matched cannabis users to nonusers on 1:1 ratio (4,728:4,728), using a propensity-based matching system, with a stringent algorithm. We then used conditional regression models with generalized estimating equations to measure the adjusted prevalence rate ratio (aPRR) for having liver cirrhosis (and its complications), carcinoma, mortality, discharge disposition, and the adjusted mean ratio (aMR) of total hospital cost and length of stay (LOS) [SAS 9.4]. RESULTS: Our study revealed that cannabis users (CUs) had decreased prevalence of liver cirrhosis (aPRR: 0.81[0.72-0.91]), unfavorable discharge disposition (0.87[0.78-0.96]), and lower total health care cost ($39,642[36,220-43,387] versus $45,566[$42,244-$49,150]), compared to noncannabis users (NCUs). However, there was no difference among CUs and NCUs on the incidence of liver carcinoma (0.79[0.55-1.13]), in-hospital mortality (0.84[0.60-1.17]), and LOS (5.58[5.10-6.09] versus 5.66[5.25-6.01]). Among CUs, dependent cannabis use was associated with lower prevalence of liver cirrhosis, compared to nondependent use (0.62[0.41-0.93]). CONCLUSIONS: Our findings suggest that cannabis use is associated with decreased incidence of liver cirrhosis, but no change in mortality nor LOS among HCV patients. These novel observations warrant further molecular mechanistic studies. Hindawi 2018-09-23 /pmc/articles/PMC6174743/ /pubmed/30345261 http://dx.doi.org/10.1155/2018/9430953 Text en Copyright © 2018 Adeyinka Charles Adejumo et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Adejumo, Adeyinka Charles Adegbala, Oluwole Muyiwa Adejumo, Kelechi Lauretta Bukong, Terence Ndonyi Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis |
title | Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis |
title_full | Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis |
title_fullStr | Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis |
title_full_unstemmed | Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis |
title_short | Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis |
title_sort | reduced incidence and better liver disease outcomes among chronic hcv infected patients who consume cannabis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174743/ https://www.ncbi.nlm.nih.gov/pubmed/30345261 http://dx.doi.org/10.1155/2018/9430953 |
work_keys_str_mv | AT adejumoadeyinkacharles reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis AT adegbalaoluwolemuyiwa reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis AT adejumokelechilauretta reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis AT bukongterencendonyi reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis |